Aims: To compare the proliferating cell nuclear antigen
(PCNA) and nm23 gene product expression in invasive
duct carcinoma breast with other clinicopathologic parameters,
trying to assess their prognostic significance in
these neoplasms.
Methods: The monoclonal antibody PCIO and antihuman
nm23 protein were used to detect PCNA and nm23-
HI and H2 gene product immunoreactivety in 86 invasive
duct carcinoma breast. PCNA labeling index (LI) and
nm23 expression score were calculated and compared with
other clinicopathologic parameters of the neoplasms examined.
Results: There was a significant inversely proportionate
correlation between nm23 expression and tumor stage
< 0.05). Also, there were negative significant correlations
between nm23 and lymph node metastasis and a positive
significant one between nm23 expression and 5-year
free survival (p < 0.05). PCNA LI was also significantly
proportionate with high grade (p < 0.05). Also, there were
a negative significant correlation between PCNA expression
and 5-year free survival (p <0.05).
Conclusion: nm23 gene product and PCNA detected
by immunohistochemical methods may be considered as
additional prognostic parameters which may potentially influence
the clinical behavior of breast cancer and may be
utilized besides all other clinic-pathologic data to asses |
